Trial Profile
An open, non-randomized phase-2 study of efficacy and safety of treatment with 177Lutetium-DOTA0-Tyr3-octreotate in patients with neuroendocrine tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2011
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 15 Jun 2011 New trial record